0001415889-24-005544.txt : 20240227 0001415889-24-005544.hdr.sgml : 20240227 20240227171008 ACCESSION NUMBER: 0001415889-24-005544 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240223 FILED AS OF DATE: 20240227 DATE AS OF CHANGE: 20240227 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Siatis Perry C CENTRAL INDEX KEY: 0001951400 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35565 FILM NUMBER: 24688355 MAIL ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AbbVie Inc. CENTRAL INDEX KEY: 0001551152 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 320375147 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 BUSINESS PHONE: (847) 932-7900 MAIL ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 4 1 form4-02272024_050202.xml X0508 4 2024-02-23 0001551152 AbbVie Inc. ABBV 0001951400 Siatis Perry C 1 N. WAUKEGAN ROAD NORTH CHICAGO IL 60064 false true false false EVP, GC AND SECRETARY 1 Common Stock, $0.01 par value 2024-02-23 4 M 0 2919 144.54 A 31092 D Common Stock, $0.01 par value 2024-02-23 4 M 0 3519 105.92 A 34611 D Common Stock, $0.01 par value 2024-02-23 4 M 0 7315 149.62 A 41926 D Common Stock, $0.01 par value 2024-02-23 4 S 0 13753 177.51 D 28173 D Option (Right to buy) 144.54 2024-02-23 4 M 0 2919 144.54 A 2023-02-17 2032-02-16 Common Stock 2919 2919 D Option (Right to buy) 105.92 2024-02-23 4 M 0 3519 105.92 A 2022-02-18 2031-02-17 Common Stock 3519 0 D Option (Right to buy) 149.62 2024-02-23 4 M 0 7315 149.62 A 2024-02-16 2033-02-15 Common Stock 7315 14629 D This sale was executed pursuant to a Rule 10b5-1 plan that was entered into by the Reporting Person on November 1, 2023. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $177.01 to $177.73, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. T.O. Odutayo, attorney-in-fact for Perry C. Siatis 2024-02-27